Flux across microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro (Pharmaceutical Research DOI: 10.1007/s11095-008-9578-3);Flux across of microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro

Pharmaceutical Research

Volumn 25, Issue 7, 2008, Pages 1677-1685

  Banks, Stan L ^a   Pinninti, Raghotham R ^a   Gill, Harvinder S ^b   Crooks, Peter A ^a   Prausnitz, Mark R ^b,c   Stinchcomb, Audra L ^a  

^a University of Kentucky   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c Georgia Institute of Technology   (United States)

Author keywords

6 naltrexol; Microneedle; Naltrexone; Protonation; Transdermal

Indexed keywords

6 BETA NALTREXOL; DRUG METABOLITE; NALTREXOL; NALTREXONE; 6 BETA HYDROXYNALTREXONE; 6 BETA-HYDROXYNALTREXONE; DRUG DERIVATIVE; NARCOTIC ANTAGONIST;

ANIMAL TISSUE; ARTICLE; DRUG ABSORPTION; DRUG DIFFUSION; DRUG PENETRATION; DRUG SOLUBILITY; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYDROPHILICITY; IN VITRO STUDY; IONIZATION; NEEDLE; NONHUMAN; PH; PRIORITY JOURNAL; PROTON TRANSPORT; SKIN ABSORPTION; SKIN PERMEABILITY; TRANSDERMAL DRUG ADMINISTRATION; ANIMAL; CHEMISTRY; DIFFUSION; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; PHYSICAL CHEMISTRY; PHYSIOLOGY; STIMULATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; DIFFUSION; GUINEA PIGS; HYDROGEN-ION CONCENTRATION; NALTREXONE; NARCOTIC ANTAGONISTS; NEEDLES; PHYSICAL STIMULATION; SKIN ABSORPTION; SKIN PHYSIOLOGY;

EID: 44649083690     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9627-y     Document Type: Erratum

References (28)

1. T.L. Mark, R.M. Coffey, R. Vandivort-Warren, H.J. Harwood, and E.C. King. U.S. spending for mental health and substance abuse treatment, 1991-2001. Health Aff (Millwood). Suppl Web Exclusives:W5-133-W135-142 (2005).
2. SAMHSA. Results from the 2006 National Survey on Drug Use and Health: National Findings, Department of Health and Human Services: Substance Abuse and Mental Health Services Administration Office of Applied Studies, 2006, pp. 1-282.
3. J. A. Bouwstra, P. L. Honeywell-Nguyen, G. S. Gooris, and M. Ponec. Structure of the skin barrier and its modulation by vesicular formulations. Prog. Lipid Res. 42:1-36 (2003).
4. NIDA. Treatment for Drug Abusers in the Criminal Justice System, National Institutes of Health and National Institute on Drug Abuse, July 2006.
5. ACS. Cancer Facts and Figures 2007, American Cancer Society, 2007, pp. 1-56.
6. PDR. Generics second edition. Medical Economics. New Jersey, 1996, pp. 1083-1086.
7. C. Alkermes. Vivitrol™ (naltrexone for extended-release injectable suspension). http://www.vivitrol.com/.
8. G. P. Galloway, M. Koch, R. Cello, and D. E. Smith. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychiatry. 5:1-10 (2005).
9. D. C. Hammell, M. Hamad, H. K. Vaddi, P. A. Crooks, and A. L. Stinchcomb. A duplex "Gemini" prodrug of naltrexone for transdermal delivery. J. Control. Release. 97:283-290 (2004).
10. D. C. Hammell, E. I. Stolarczyk, M. Klausner, M. O. Hamad, P. A. Crooks, and A. L. Stinchcomb. Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent. J. Pharm. Sci. 94:828-836 (2005).
11. B. N. Nalluri, C. Milligan, J. Chen, P. A. Crooks, and A. L. Stinchcomb. In vitro release studies on matrix type transdermal drug delivery systems of naltrexone and its acetyl prodrug. Drug Dev. Ind. Pharm. 31:871-877 (2005).
12. M. R. Prausnitz, S. Mitragotri, and R. Langer. Current status and future potential of transdermal drug delivery. Nat. Rev. 3:115-124 (2004).
13. M. S. Gersteland, and V. A. Place. Drug delivery device, Alza CorporationIn U. S. P. Office (ed.), Vol. 3,964,482, Alza Corporation, USA, 1976, pp. 1-13.
14. M. R. Prausnitz. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. 56:581-587 (2004).
15. M. R. Prausnitz, J. A. Mikszta, and J. Raeder-Devens. Microneedles in percutaneous penetration enhancers. In E. Smith and H. Maibach (eds.), CRC, Boca Raton, FL, 2005, pp. 239-255.
16. S. A. Coulman, D. Barrow, A. Anstey, C. Gateley, A. Morrissey, N. Wilke, C. Allender, K. Brain, and J. C. Birchall. Minimally invasive cutaneous delivery of macromolecules and plasmid DNA via microneedles. Curr. Drug Deliv. 3:65-75 (2006).
17. J. G. E. Gardeniers, J. W. Luttge, J. W. Berenschott, M. J. de Boer, Y. Yeshurun, M. Hefetz, R. van't Oever, and A. van den Berg. Silicon micromachined hollow microneedles for transdermal liquid transport. J. MEMS. 6:855-862 (2003).
18. M. Cormier, B. Johnson, M. Ameri, K. Nyam, L. Libiran, D. D. Zhang, and P. Daddona. Transdermal delivery of desmopressin using a coated microneedle array patch system. J. Control. Release. 97:503-511 (2004).
19. W. Martanto, S. P. Davis, N. R. Holiday, J. Wang, H. S. Gill, and M. R. Prausnitz. Transdermal delivery of insulin using microneedles in vivo. Pharm. Res. 21:947-952 (2004).
20. J. A. Mikszta, J. B. Alarcon, J. M. Brittingham, D. E. Sutter, R. J. Pettis, and N. G. Harvey. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat. Med. 8:415-419 (2002).
21. S. Kaushik, A. H. Hord, D. D. Denson, D. V. McAllister, S. Smitra, M. G. Allen, and M. R. Prausnitz. Lack of pain associated with microfabricated microneedles. Anesth. Analg. 92:502-504 (2001).
22. B. R. de Costa, M. J. Iadarola, R. B. Rothman, K. F. Berman, C. George, A. H. Newman, A. Mahboubi, A. E. Jacobson, and K. C. Rice. Probes for narcotic receptor mediated phenomena. 18. Epimeric 6 alpha- and 6 beta-iodo-3,14- dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluation, and radiochemistry of [125I]-6 beta-iodo-3,14-dihydroxy-17- (cyclopropylmethyl)-4,5 alpha-epoxymorphinan. J. Med. Chem. 35:2826-2835 (1992).
23. K. S. Paudel, B. N. Nalluri, D. C. Hammell, S. Valiveti, P. Kiptoo, M. O. Hamad, P. A. Crooks, and A. L. Stinchcomb. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo. J. Pharm. Sci. 94:1965-1975 (2005).
24. J. Liu, and Z. Gong. Progress of research on naltrexol. Zhongguo Yaowu Yilaixing Zazhi. 14:89-92 (2005).
25. R. L. Bronaugh, and R. F. Stewart. Methods for in vitro percutaneous absorption studies III: hydrophobic compounds. J. Pharm. Sci. 73:1255-1258 (1984).
26. M. A. Hussain, C. A. Koval, M. J. Myers, E. G. Shami, and E. Shefter. Improvement of the oral bioavailability of naltrexone in dogs: a prodrug approach. J. Pharm. Sci. 76:356-358 (1987).
27. H. K. Vaddi, M. O. Hamad, J. Chen, S. L. Banks, P. A. Crooks, and A. L. Stinchcomb. Human skin permeation of branched-chain 3-0-alkyl ester and carbonate prodrugs of naltrexone. Pharm. Res. 22:758-765 (2005).
28. S. Valiveti, D. C. Hammell, K. S. Paudel, M. O. Hamad, P. A. Crooks, and A. L. Stinchcomb. In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. J. Control. Release. 102:509-520 (2005).